An interventional study of Methylcobalamin and Injection lidocaine in Subacute Herpetic Neuralgia, sponsored by CMH Multan Institute of Medical Sciences. Recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by CMH Multan Institute of Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Neuralgia with a site in Pakistan — 4 open to participants now, 6 under way, none of them phase 3. Neuralgia · Pakistan.
Among the 16 studies in Neuralgia with a site in Pakistan, this one is the 7th largest by planned enrollment, is one of 6 that started in 2026, is one of 14 with no phase, and was the 16th registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →4 of the 16 studies in Neuralgia with a site in Pakistan are open now. Recruiting first, the newest first:
University of Faisalabad · Sites in Pakistan
Ages 40–60
Dow University of Health Sciences · Sites in Pakistan
Ages 40–65
Ibadat International University, Islamabad · Sites in Pakistan
Ages 40+
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 52 across 831 interventional studies indexed under Neuralgia.
Median enrollment 60 across the 16 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 10 most frequent:
CMH Multan Institute of Medical Sciences is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
CMH Multan Institute of Medical Sciences has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
3 of the studies in Neuralgia with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905729University of Management and Technology LahoreComparative Effects of tDCS and tACS on Pain, Dexterity, and Strength in Diabetic Peripheral Neuropathy | 2026-12-31 |
| NCT07695181Ibadat International University, IslamabadEffectiveness of Pain Neuroscience Education Along With Neural Mobilization Versus Neural Mobilization Alone on Pain, Functional Disability And Quality of Life In Patients With Diabetic Neuropathic Pain | 2027-01-10 |
| NCT07938242CMH Multan Institute of Medical SciencesComparison of Local Methylcobalamin and Subcutaneous Lidocaine in Subacute Herpetic Neuralgia | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Neuralgia with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial will compare methylcobalamin and lidocaine injections for pain relief in 60 patients with subacute herpetic neuralgia over four weeks.
This randomized controlled trial will compare the efficacy of local subcutaneous methylcobalamin injection versus subcutaneous lidocaine injection in patients aged 40-70 years with unilateral subacute herpetic neuralgia and baseline pain score greater than 6 on the visual analogue scale (VAS). A total of 60 patients will be randomly allocated to two groups, with 30 patients in each group. Group A will receive methylcobalamin injection (1 mg/2 mL), while Group B will receive lidocaine injection (1%, 2 mL), six times per week for four weeks. Pain intensity and sleep disturbance will be assessed at baseline and after 28 days of treatment. Treatment efficacy will be defined as a pain score below 3 at the end of treatment. Adverse effects will also be monitored and recorded. The study will be conducted at the Department of Dermatology, Combined Military Hospital (CMH), Multan, over six months following synopsis approval.
>Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive local subcutaneous methylcobalamin injection (1 mg/2 mL), six times per week for four weeks.
Drug: Methylcobalamin
Participants will receive local subcutaneous lidocaine injection (1%, 2 mL), administered six times per week for four weeks.
Drug: Injection lidocaine
Methylcobalamin injection (1 mg/2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.
Lidocaine inLidocaine injection (1%, 2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.
Pain score
Change in pain intensity measured using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (maximum bearable pain). Treatment efficacy is defined as a pain score below 3 at 28 days after randomization.
Time frame: Baseline (Day 1) and Day 28 (end of treatment).
Sleep Disturbance Score
Sleep disturbance assessed using a numeric rating scale ranging from 0 (no disturbance) to 10 (severe disturbance).
Time frame: Baseline (Day 1) and Day 28 (end of treatment).
Adverse Effects
Assessment and recording of adverse effects, including redness, swelling, hematoma formation, dizziness, and urticaria following injections.
Time frame: Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.
PDFs hosted by the registry, ClinicalTrials.gov.
Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.
Of 246 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 6 months is below that.
Counting every sponsor, half of 264 studies reached it within 24 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mecobalamin
CMH Multan Institute of Medical Sciences